NasdaqOphthotech (OPHT) Q4 Earnings Beat, Gene Therapy in FocusNasdaqOphthotech CorporationOPHT reported loss of 26 cents per share for the fourth quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 58 cents as well as a loss of $… Continue reading
CAR T-cell therapy may serve as bridge to transplantation for ALLHealioSALT LAKE CITY — Chimeric antigen receptor T-cell therapy may have a synergistic role with hematopoietic stem cell transplantation to improve leukemia-free survival without an incre… Continue reading
Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare …GlobeNewswire (press release)As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the … Continue reading
Gene Therapy Holds Out Hope for DiabeticsPR Newswire (press release)Since its first successful use nearly 30 years ago, gene therapy has grown into an important if experimental part of the medical sector. Now it is taking off in a big way, offering tre… Continue reading
BioPharma-Reporter.comGene therapy demand drives VGXI to up Texan GMP capabilitiesBioPharma-Reporter.comThe new capabilities come as a response to growing demand for gene therapy products, business development manager Christy Franco told Biopharma-Repo… Continue reading
Pulmonary Fibrosis NewsNewly Identified Stem Cells Have Potential to Regenerate Blood VesselsPulmonary Fibrosis NewsA new subtype of stem cells that have the unique ability to perform two distinct functions at the same time was recently discovered by r… Continue reading
Genetic Literacy Project |
CAR–T cell therapy could drive a ‘revolution’ in cancer treatments
Genetic Literacy Project [T]he United States Food and Drug Administration (FDA) made the landmark decision to approve two ‘drugs’ that use CAR–T cell therapy – the injection of engineered immune cells into patients – to treat blood cancers. First, in August 2017 it approved … |